Hardly a powerhouse, the XLTE-ready 4.5 incher goes up against Motorola’s Android-based Moto Es at a no-contract starting price of $120.
Almost five years of waiting, and this is the best LG can do to prove Microsoft’s mobile-centric Windows ecosystem has a future? The once mighty Optimus 7 must be turning over in its grave. Then again, we were warned time and time again not to expect the world from the Verizon-exclusive Lancet.
Most likely, we’re looking at a short test drive ahead of a bigger, glitzier, wider-scale Windows 10 release. Can you say LG G4 for Windows? That’s probably what’s next, alongside a tiled equivalent of HTC’s underwhelming One M9 and perhaps a long overdue sequel for Samsung’s ATIV SE.
Of course, the low-end Lancet should itself be more than capable of scoring a Win 10 update OTA before leaves begin to fall. After all, Redmond insisted of late 512 MB RAM is plenty to run their disrupting looming OS iteration. And LG’s platform comeback packs twice the random-access memory.
Also, a respectably speedy 64-bit quad-core Snapdragon 410 processor. So far, the bang for the 120 bucks sounds positively mind-blowing, with an 8 MP rear-facing camera making the deal even sweeter. ‘
Too bad the 4.5-inch 480 x 854 display can’t keep up with 2015 standards. That’s unfortunately not enough to eclipse the pixel count of the $90 first-gen Moto E, though clearly, Lancet’s strengths lie elsewhere.
The battery, for instance, is quite sizable, at 2,100 mAh, so Big Red probably doesn’t lie when claiming the phone can last up to 420 hours in standby time and 18.5 hours of continuous usage. Tipping the scales at a little over 5 ounces, the Lancet also offers 8 GB internal storage, microSD support, a VGA front cam and several neat software tricks borrowed from its Google-powered relatives. You know, KnockOn, QuickMemo and whatnot.
Lastly, you should note America’s largest wireless network sells the low-cost WP device at $20 with contracts or $5 a month on Edge plans in addition to the outright $120. Bottom line, they’re certainly trying to make the Lancet as appealing as possible.